Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Hierarchical Microgel–Lipid Nanoparticle Delivery for Colon

    2026-06-08

    Microfluidized Dextran–Trilaurin Lipid Nanoparticle System for Oral Colon Cancer Therapy

    Study Background and Research Question

    Colorectal cancer remains a leading cause of cancer-related mortality, with survival rates plummeting from approximately 90% in localized cases to just 14% for metastatic disease. While standard treatments combine surgical resection and intravenous chemotherapy, oral chemotherapeutic options remain limited due to poor drug stability in the gastrointestinal (GI) environment, low systemic bioavailability, and barriers to effective colon targeting. Nanoparticle (NP) platforms offer potential to improve these limitations by protecting drugs from degradation and enhancing local delivery, but are often hindered by rapid GI clearance and insufficient tumor targeting. The central question addressed by Lu et al. is whether a hierarchically targeted delivery system can overcome these barriers to enable effective and localized oral chemotherapy for colon cancer.

    Key Innovation from the Reference Study

    The central innovation lies in constructing a multifunctional delivery system: microfluidized dextran microgels encapsulating lipid nanoparticles (LNPs) that co-deliver cisplatin and superparamagnetic iron oxide nanoparticles (SPIONs). Critically, the LNPs are formulated using trilaurin (glycerol tridodecanoate), a long-chain triacylglycerol C12 excipient, enabling both drug solubilization and nanoparticle stability. The microgel matrix is dual-modified with dextran and folic acid (FA) residues, providing sequential targeting: microgel retention in the colon via dextran, and enhanced uptake by colon cancer cells through FA receptor recognition. The microgels are engineered to degrade specifically in the colon, releasing the LNPs at the target site and enabling combined chemotherapeutic and magnetothermal treatment through SPION activation. This approach addresses both the physical and biological barriers to oral delivery of hydrophobic drugs and nanoparticles.

    Methods and Experimental Design Insights

    The study employs a sophisticated microfluidization process to produce dextran-based microgels, which encapsulate trilaurin-based LNPs loaded with cisplatin and SPIONs. Key methodological features include:

    • Microfluidized crosslinking of dextran to form microgels with controlled size and porosity.
    • Surface modification with dextran and folic acid to achieve dual targeting.
    • Encapsulation of trilaurin-based LNPs within the microgel matrix, enabling the co-delivery of chemotherapeutic (cisplatin) and magnetically responsive (SPION) agents.
    • Enzymatic degradation of microgels is triggered by colonic dextranase, releasing the LNPs specifically in the colon.
    • Use of in vitro and in vivo models to assess GI retention, targeted uptake, antitumor efficacy, and reduction of metastatic spread.

    This platform takes advantage of trilaurin's physicochemical properties as a lipid excipient for solid lipid microparticles and nanoparticles, providing both drug loading capacity and compatibility with hydrophobic agents.

    Protocol Parameters

    • Microfluidized dextran microgel formation: Crosslink dextran via microfluidization to achieve uniform particle size distribution and optimize encapsulation efficiency for LNPs.
    • Trilaurin-based LNP preparation: Dissolve trilaurin and co-encapsulate cisplatin and SPIONs; typically, trilaurin concentrations should be adjusted to ensure nanoparticle stability and drug solubilization, considering its solubility profile in ethanol and DMSO.
    • Surface modification: Conjugate folic acid and additional dextran residues to the microgel surface to enable sequential targeting.
    • Enzymatic release mechanism: Design for microgel degradation by colonic dextranase, allowing for spatially controlled LNP release in the colon.
    • In vivo evaluation: Administer the microgel–LNP system orally in murine orthotopic colon cancer models to assess tumor retention, uptake, and therapeutic outcomes.

    Core Findings and Why They Matter

    Encapsulation of trilaurin-based LNPs within dextran microgels achieved several key outcomes, as detailed in the reference study:

    • Enhanced colon localization: The microgel shell provided prolonged GI retention and minimized premature absorption in the small intestine, allowing for targeted delivery to the colon.
    • Sequential targeting: Dextran residues promoted microgel adhesion to the colon mucosa, while FA modification enhanced uptake by FA receptor-overexpressing colon cancer cells.
    • Triggered release: Microgels degraded specifically in response to colonic dextranase, releasing LNPs at the desired anatomical site.
    • Dual therapy efficacy: The co-delivery of cisplatin and SPIONs enabled both chemotherapy and localized magnetothermal therapy, resulting in significant inhibition of tumor growth and metastasis in orthotopic models.
    • Minimized systemic toxicity: The system reduced off-target drug absorption, highlighting an improved therapeutic index for oral chemotherapeutics.

    Collectively, these findings point to a robust strategy for overcoming major barriers in oral delivery of peptide and protein drugs, as well as small molecule chemotherapeutics, by leveraging the lipid excipient properties of trilaurin within a hierarchically structured delivery vehicle.

    Comparison with Existing Internal Articles

    The findings of Lu et al. align with and extend several prior workflow-oriented analyses of trilaurin's role in nanoparticle formulation and oral drug delivery:

    These internal resources collectively underscore trilaurin's versatility in biocatalytic and drug delivery workflows, with the reference study serving as a detailed in vivo demonstration of its translational potential.

    Limitations and Transferability

    Despite its promising results, the described delivery system faces certain limitations and considerations for broader application:

    • Species and model specificity: Efficacy and safety data are currently limited to murine orthotopic colon cancer models. Human translation will require additional pharmacokinetic, toxicity, and efficacy testing.
    • Formulation constraints: Trilaurin's insolubility in water and the need for precise storage conditions (as highlighted in the product documentation) may limit scalability for some aqueous formulations or long-term storage.
    • Enzymatic release reliance: The system depends on colon-specific dextranase activity, which may vary across patient populations or disease states.

    Nevertheless, the platform's modularity and reliance on well-characterized excipients such as trilaurin support its adaptability in related oral nanoparticle delivery strategies.

    Research Support Resources

    For researchers aiming to implement or adapt similar oral delivery systems, Trilaurin (SKU BA7536) is available as a well-characterized lipid excipient and substrate suitable for solid lipid microparticle and nanoparticle protocols. APExBIO provides detailed specifications, including solubility profiles and storage recommendations, that align with the requirements for advanced nanoparticle formulation workflows. As with any lipid excipient, strict adherence to protocol and compatibility assessment are recommended to ensure reproducibility and efficacy in new delivery systems.